Business Context and Reporting Period
This Form 8-K Current Report was filed by Crinetics Pharmaceuticals, Inc. on December 17, 2025, regarding events occurring on December 16, 2025. The filing discloses the departure of a senior executive and the execution of related transition and advisory agreements.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
- Severance Payment: $577,000 (equal to twelve months of base salary).
- Legal Fee Reimbursement: Up to $15,000.
- Training Course Cost: Up to $6,500.
- COBRA Premiums: Reimbursed for up to 12 months post-transition.
- Advisory Compensation: $600 per hour for services rendered between April 1, 2026, and March 30, 2028.
Material Changes
The primary material change is the departure of Dana Pizzuti, M.D., as Chief Medical and Development Officer, effective December 31, 2025. Dr. Pizzuti will transition to a Strategic Regulatory and Development Advisor role starting January 1, 2026, followed by a formal Advisory Agreement commencing April 1, 2026.
Outlook, Risks, and Unusual Items
Management Commentary and Transition: The company has structured a phased transition to ensure continuity of regulatory and development services. Dr. Pizzuti will provide transition services through March 31, 2026, and advisory services thereafter.
Equity Vesting: Outstanding equity awards will continue to vest during the engagement period. In the event of a Change in Control, unvested awards vest automatically if the acquirer does not assume them and Dr. Pizzuti continues providing services.
Risks and Contingencies: The agreements include standard provisions for termination for Cause. The company has secured a general release of all claims from Dr. Pizzuti regarding her employment and departure.
Investor Verification Checklist
- Verify the total cash outflow impact of the severance package ($577,000) and potential bonus accruals.
- Review the specific scope of "Transition Services" and "Advisory Services" in the attached Exhibits 10.1 and 10.2.
- Confirm the timeline for appointing a permanent replacement for the Chief Medical and Development Officer role.
- Assess the impact of the executive departure on ongoing clinical trials or regulatory submissions.